PCBL Q1: consolidated PAT surges 65% YoY to ₹155 Cr as carbon black margins recover

PCBL Chemical's Q1 FY27 print delivered the margin-led recovery the market was waiting for. Consolidated net profit rose to ₹154.93 Cr, up 64.6% from ₹94.10 Cr a year ago, on revenue of ₹2,473.37 Cr (+17.0% YoY). The steep sequential jump (₹40.22 Cr in Q4) overstates the improvement — the March quarter was depressed by weak margins and a ₹4.19 Cr Labour-Codes exceptional — so the ~65% YoY figure is the clean read, since neither Q1 period carried one-offs. Consolidated operating margin widened to 14.76% (from 13.85% YoY) and net margin to 6.29% (from 4.47%), confirming that the margin normalisation management had guided for is under way.

Carbon Black did the heavy lifting: segment revenue of ~₹2,004 Cr (+20.5% YoY) and segment PBIT of ₹315.8 Cr (+39% YoY) reflect both record volumes and recovering per-tonne spreads. The Aquapharm-led Chemical segment was the soft spot — revenue of ₹393.8 Cr grew just 3% YoY and segment profit slipped to ₹10.7 Cr (from ₹14.5 Cr), well short of the 20-25% revenue growth and ₹75 Cr quarterly EBITDA run-rate management targeted on the Q4 call. Battery Chemicals remains pre-revenue despite the June commissioning of a 20,000 MTPA specialty line at Mundra and the appointment of a Chief–Batteries. The consolidated-vs-standalone divergence is material and worth flagging: standalone PAT was ₹107.24 Cr, up a more modest ~15% YoY, so the outsized consolidated growth is essentially a subsidiary swing — international carbon black and Aquapharm entities contributed roughly ₹48 Cr net this quarter against near-breakeven a year ago.

The stock went into the print at ₹334.55, up 4.2% over the past month of trading.

For context: this is the highest quarterly PAT in the last 6 quarters on our records; PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.

Against management's own guidance the quarter reads as met on the core: the promised FY27 recovery with double-digit carbon-black EBITDA growth clearly materialised, even as Aquapharm is not yet tracking its target. There is no published Street consensus to grade against — results landed on the earnings-call day (July 29) — but the two things investors had flagged going in, volume growth and margin recovery, both showed up. Balance-sheet actions supported the bull case: finance costs fell to ₹92.5 Cr from ₹112.4 Cr YoY and consolidated debt-equity eased to 1.25 (from 1.39), consistent with the de-leveraging commitment, while the Board declared a ₹4.50/share (450%) interim dividend and the company had redeemed ₹200 Cr of commercial paper in July.